Navigation Links
Net advantage
Date:3/7/2013

Malaria, the leading cause of death among children in Africa, could be eliminated if three-fourths of the population used insecticide-treated bed nets, according to a new study from the National Institute for Mathematical and Biological Synthesis (NIMBioS).

The study, which uses a mathematical model, found that use of insecticide-treated bed nets or ITNs positively affected the infection's reproduction number, or R, which is the primary epidemiological number used to determine the degree which a disease can spread through a population. The model concludes that if 75 percent of the population were to use ITNs, malaria could be eliminated.

The treated mosquito net forms a protective barrier around people sleeping under them. The insecticide not only kills the mosquitoes, which carry the malaria parasite, and other insects, it also repels mosquitoes, reducing the number that enter the house and attempt to feed on people inside. With ITNs, the number of mosquitoes, as well as their length of life, is reduced, which is why the density of nets in a community is important.

Overcoming cultural resistance to using bed nets in communities where people view the nets as intrusive has been a major challenge of international malaria prevention agencies, however. There is evidence also that in some countries more bed nets go to the rich than the poor. Health groups are devising strategies to encourage use of the bed nets and to make sure they are distributed more equitably.

"Based on the results, it's clear that educational campaigns around the use of bed-nets must continue as the nets play a critical role in reducing the transmission of malaria," said Folashade Agusto, the study's lead author and participant in the NIMBioS Investigative Workshop on Malaria Modeling and Control, whose other participants co-authored the study. A former NIMBioS postdoctoral fellow, Agusto is an assistant professor of mathematics at Austin Peay State University.

Malaria has already been eradicated in Europe, North America, the Caribbean, and parts of Asia and South-Central America, and yet, the World Health Organization estimates that every year 250 million people become infected with malaria and nearly one million die.


'/>"/>

Contact: Catherine Crawley
ccrawley@nimbios.org
865-974-9350
National Institute for Mathematical and Biological Synthesis (NIMBioS)
Source:Eurekalert

Related biology news :

1. Video-gaming fish play out the advantages of groups
2. Syracuse University study finds autumn advantage for invasive plants in eastern United States
3. Weakness can be an advantage in surviving deadly parasites, a new study shows
4. Evolving to fight epidemics: Weakness can be an advantage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... Delpor, ... a $224K grant from the National Institute of Mental Health (NIMH) for the further ... on Delpor’s PROZOR technology and is expected to deliver therapeutic levels of ...
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology: